

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number

WO 2023/031799 A1

(51) International Patent Classification:

C07D 307/81 (2006.01) A61K 31/343 (2006.01)
C07D 405/04 (2006.01) A61K 31/443 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2022/058131

(22) International Filing Date:

30 August 2022 (30.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/115963

01 September 2021 (01.09.2021) CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **LIU, Bo**; CHINA NOVARTIS INSTITUTES
FOR BIOMEDICAL RESEARCH CO., LTD., 4218 Jinke
Road, Pudong New Area, Shanghai, Shanghai 201203 (CN).
LI, Runyan; CHINA NOVARTIS INSTITUTES FOR
BIOMEDICAL RESEARCH CO., LTD., 4218 Jinke Road,
Pudong New Area, Shanghai, Shanghai 201203 (CN).
MUTZ, Michael; Novartis Pharma AG, Postfach, 4002
Basel (CH). **YUAN, Lina**; CHINA NOVARTIS INSTI-
TUTES FOR BIOMEDICAL RESEARCH CO., LTD.,
4218 Jinke Road, PUDONG New Area, Shanghai, Shang-
hai 201203 (CN). **ZHOU, Yingcong**; CHINA NOVARTIS
INSTITUTES FOR BIOMEDICAL RESEARCH CO.,
LTD., 4218 Jinke Road, Pudong New Area, Shanghai,
Shanghai 201203 (CN).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: CRYSTALLINE FORMS OF BIARYL YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS

(57) Abstract: The present invention generally relates to crystalline polymorphic forms of the biaryl YAP/TAZ-TEAD protein-protein interaction inhibitors 4-((2S,4S)-5-Chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide and 2-((2S,3S,4S)-5-Chloro-6-fluoro-3-methyl-2-((methyldamino)methyl)-2-phenyl-2,3-dihydrobenzofuran-4-yl)-3-fluoro-4-methoxybenzamide and salts thereof, as well as methods of using the forms in the treatment of cancer.

WO 2023/031799 A1